SERPING1 and hereditary angioedema: An independent Data Monitoring Committee (DMC) will assess safety, oversee study conduct, and provide recommendations on dose-escalation and expansion for each of the planned dose cohorts based on safety evaluations in conjunction with C1-INH functional plasma protein levels and HAE attack occurrences.